XORTX Therapeutics Inc.
corporate_fare Company Profile
XORTX Therapeutics Inc. (NASDAQ:XRTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for XRTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-18, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for XRTX spans 6-K, 424B4, 20-F.
Recent high-impact activity:
- XORTX Sets Q4 2026 FDA IND Submission for Gout Drug XORLO™, Targets NDA in About a Year
- XORTX Targets Q4 FDA Filing for Gout Drug, Sees $700M Market
- XORTX Re-Engages IR Agency with $2.5M Non-Refundable Fee After Delisting
- XORTX Recovers $2.5M from Terminated IR Program, Discloses $240K Acquisition Fee
- XORTX Reports $2.5M Loss, Going Concern Warning, and Material Weakness
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 76,755 shares in XRTX as of the September 15, 2026 settlement, a 424.5% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On October 2, 2026, 5.4% of XRTX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for XRTX, detected from its recent SEC filings · based on capital-structure filings through 2026-05-19.
Public Offering Finalized · Significant Dilution
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
XRTX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.